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Abstract: The aim of the study was to evaluate sleep duration and sleep variability in relation to
serum uric acid (SUA) concentrations and SUA to creatinine ratio. This is a cross-sectional analysis
of baseline data from 1842 elderly participants with overweight/obesity and metabolic syndrome
in the (Prevención con Dieta Mediterránea) PREDIMED-Plus trial. Accelerometry-derived sleep
duration and sleep variability were measured. Linear regression models were fitted to examine the
aforementioned associations. A 1 hour/night increment in sleep duration was inversely associated
with SUA concentrations (β = −0.07, p = 0.047). Further adjustment for leukocytes attenuated this
association (p = 0.050). Each 1-hour increment in sleep duration was inversely associated with SUA
to creatinine ratio (β = −0.15, p = 0.001). The findings of this study suggest that longer sleep duration
is associated with lower SUA concentrations and lower SUA to creatinine ratio.
Keywords: sleep duration; actigraphy; serum uric acid; serum uric acid to creatinine ratio
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1. Introduction
Uric acid is a terminal product of purine degradation, and high levels of circulating uric acid
have been associated with gout, type 2 diabetes (T2D), and renal and cardiovascular diseases [1].
Recently, a higher serum uric acid (SUA) to creatinine ratio was associated with an increased risk
of metabolic syndrome [2], and predicted chronic kidney disease incidence in T2D patients [3] and
chronic obstructive pulmonary disease as compared to uric acid alone [4]. Growing evidence also
suggests that elevated SUA levels are frequently identified in patients with obstructive sleep apnea [5],
possibly due to elevations in catecholamine levels [6] and intermittent hypoxia. Loss of sleep may also
contribute to raised nocturnal catecholamine levels [7].
Sleep is a crucial determinant for metabolic homeostasis, and loss of sleep or disruptions of
sleep–wake patterns have been associated with metabolic impairments. Sleep deprivation and
sleep–wake cycle disturbances have been shown to activate proteolytic pathways which may affect the
balance between protein synthesis and degradation, favoring catabolism [8,9]. As a result, proteins are
broken down into their by-products, such as purines, which are metabolized to uric acid. To date, only
one study without significant results has examined associations between subjective sleep duration and
SUA levels [10].
No previous epidemiologic study has examined the association of objectively measured sleep
characteristics with SUA and uric acid to creatinine ratio. Therefore, in the present cross-sectional
study nested in the framework of the PREDIMED-Plus trial we tested the following two hypotheses:
(1) shorter sleep duration is associated with higher SUA concentrations and higher SUA to creatinine
ratio; and (2) higher sleep variability is associated with higher SUA concentrations and higher SUA to
creatinine ratio.
2. Methods
2.1. Study Design and Population
We cross-sectionally analyzed data from the PREDIMED-Plus trial, a 6-year parallel-group,
multicenter lifestyle intervention study involving 6874 participants recruited in 23 Spanish
recruiting centers. Our analysis was performed before the implementation of the energy-restricted
diet. The design of the PREDIMED-Plus trial has been described in detail elsewhere [11].
Community-dwelling adults (aged 55–75 years) with body mass index (BMI) ≥27 and <40 kg/m2,
and meeting ≥3 metabolic syndrome individual components were included [12]. As previous studies
have shown, females have a higher life expectancy than males, and since the main outcomes of
PREDIMED-Plus study are cardiovascular diseases and mortality, we decided to recruit females aged
at least 60 years and males aged equal or more than 55 in order to account for sex differences in life
expectancy. We included participants with a BMI above 27 kg/m2 following the classification used by
the Nutrition Screening Initiative [13] and adopted by Lipschitz [14], in which seniors with a BMI above
27 kg/m2 are classified as overweight. Out of the 6874 participants, data derived from accelerometry
were available in a subsample of participants (n = 1993). Seven participants were excluded due to
incomplete sleep data, resulting in a sample size of 1986 (Figure 1). Of these, 1842 participants had
available uric acid measures (Figure 1). All participants provided written informed consent, and the
study protocol and procedures were approved according to the ethical standards of the Declaration of
Helsinki by all the participating institutions: El Comité de Ética de la Investigación (CEI) Provincial
de Málaga, CEI de los Hospitales Universitarios Virgen Macarena y Virgen del Rocío, CEI de la
Universidad de Navarra, CEI de las Illes Balears, El Comitè d’Ètica d’Investigació Clínica (CEIC)
del Hospital Clínic de Barcelona, CEIC del Parc de Salut Mar, CEIC del Hospital Universitari Sant
Joan de Reus, CEI del Hospital Universitario San Cecilio, CEIC de la Fundación Jiménez Díaz, CEIC
Euskadi, CEI en Humanos de la Universidad de Valencia, CEIC del Hospital Universitario de Gran
Canaria Doctor Negrín, CEIC del Hospital Universitario de Bellvitge, CEI de Córdoba, CEI de Instituto
Madrileño De Estudios Avanzados, CEIC del Hospital Clínico San Carlos, CEI Provincial de Málaga,
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CEI de las Illes Balears, El Comité Coordinador de Ética d’Investigació (CCEI) de la Investigación
Biomédica de Andalucía, and CEIC de León.
2.2. Biochemical Analyses
Fasting blood samples were collected, and laboratory technicians, who were blinded to the
intervention group, performed biochemical analyses on fasting SUA using standard enzymatic
procedures. Serum creatinine was measured by enzymatic reaction using the Jaffe method. Leukocyte
counts were measured using an automated analyzer.
2.3. Sleep Assessment by Accelerometry
Participants were asked to wear a wrist-worn triaxial accelerometer (GENEActiv, ActivInsights
Ltd, Kimbolton, United Kingdom) on their nondominant wrist for 8 consecutive days. Detailed
methods of accelerometer data analysis are reported elsewhere [15]. The average nocturnal sleep
duration, and intra-subject standard deviation of the sleep duration were calculated.
2.4. Covariate Assessment
Information about age, sex, education, marital and employment status, smoking habits,
depression, sleep apnea, and use of sedatives was provided by structured interviews. Adherence
to an energy-restricted Mediterranean diet (MedDiet) was assessed using a 17-item questionnaire.
A systolic and/or diastolic blood pressure ≥130/85 mmHg or antihypertensive drug usage were used
to define high blood pressure. Moderate to vigorous physical activity (MVPA) was calculated and a
new binary variable was created according to compliance of the WHO recommendations for MVPA
set in ≥150 min/week [16]. T2D was defined as previous clinical diagnosis of diabetes, hemoglobin
A1C (HbA1c) ≥ 6.5%, use of antidiabetic medication, or fasting plasma glucose >126 mg/dL.
2.5. Statistical Analysis
The normal distribution of the variables was evaluated using the Kolmogorov–Smirnov test.
Participants’ characteristics according to categories of sleep duration are presented as means (±SD)
or median (interquartile range) for quantitative variables, and percentages (%) and numbers (n) for
categorical variables. These characteristics were examined across five categories of night sleep duration
(<6 h, 6 to <7 h, 7 to <8 h, 8 to <9 h, and ≥9 h) [17]. One-way ANOVA (Bonferroni post hoc analysis for
pairwise comparisons) or Kruskal–Wallis (Mann–Whitney tests in the post-hoc multiple comparisons)
and chi-squared tests were used, as appropriate, to examine between-categories differences. Linear
regression models were fitted to examine the associations of 1 h/day increment in sleep duration
and sleep variability with SUA and SUA to creatinine ratio. A number of models were examined.
For both outcomes, Model 1 was adjusted for sex and age (continuous). Model 2 was further adjusted
for BMI (continuous), marital status (single/divorced, married, widower), employment (working,
nonworking, retired), education (primary education, secondary education, academic/graduate),
smoking habit (current smoker, past smoker, never smoked), sedative treatment (yes/no), sleep
apnea (yes/no), T2D (yes/no), uric acid agents (allopurinol, febuxostat) (yes/no), hypertension
(yes/no), depression (yes/no), 17-item energy-restricted Mediterranean diet (continuous), compliance
with MVPA recommendations set at ≥150 min/week (yes/no), time spent in sustained inactivity
bouts (“daytime napping”, min/day), and intervention center. A third model was fitted by including
variables from Model 2 plus leukocytes in order to account for possible influence of this indirect
inflammatory marker in the aforementioned associations [18–20]. The variables (sleep variability and
daytime napping) that did not present a normal pattern were transformed logarithmically prior to
these analyses. We used multiple imputation methods using the Stata “MI” module (the number of
imputation was set to 20) to replace the missing values of leukocytes in 42 participants. Significance
was set at p-values < 0.05.
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3. Results
General characteristics as well as sleep and biochemical parameters for the entire population
and by categories of nocturnal sleep duration are displayed in Tables 1 and 2. The mean age of
participants was 65.0 ± 5 years and mean nocturnal sleep duration was 6.9 ± 1.1 h, while the median
sleep variability was 0.8 0.6; 1.1h, According to categories of sleep duration, those participants sleeping
less than 6 hours were more likely to be younger and male compared to all the other sleep duration
categories. They were also more likely to have a higher BMI, adhere less to an energy-restricted
MedDiet, have higher education, and be currently employed. Regarding SUA and SUA to creatinine
ratio, their values were higher in those participants sleeping less than 6 h. Spearman correlation
coefficients among uric acid, creatinine, and leukocytes are shown in Supplementary Table S1. SUA
was positively correlated with leukocytes (r = 0.11, p < 0.001).
In the fully adjusted model, a 1 hour/night increment in sleep duration was inversely associated
with SUA concentrations (β = −0.07, p = 0.047) (Table 3). Further adjustment for leukocytes attenuated
this association (p = 0.050). Furthermore, each 1-hour increment in sleep duration was inversely
associated with the ratio of SUA to creatinine (β = −0.15, p = 0.001) and remained significant even
after adjusting for leukocytes.
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Table 1. General characteristics of the study population from Prevención con Dieta Mediterránea-Plus trial across categories of nocturnal sleep duration.
Categories of Nocturnal Sleep Duration (h)
Total
n = 1842
<6 h
n = 308
6–<7 h
n = 618
7–<8 h
n = 654
8–<9 h
n = 225
≥9 h
n = 37 p-Value
Age, mean± SD, years 65 ± 5 64 ± 5 65 ± 5 65 ± 5 66 ± 4 68 ± 4 <0.001
Male, n (%) 979(53) 229(74) 348(56) 305(46) 85(38) 12(32) <0.001
BMI, mean± SD, kg/m2 32.6 ± 3.4 33.1 ± 3.5 32.5 ± 3.5 32.3 ± 3.4 32.6 ± 3.2 32.5 ± 3.4 0.031
Type 2 diabetes, n (%) 505(27) 95(31) 174(28) 170(26) 51(22) 15(40) 0.156
Sleep apnea, n (%) 237(13) 49(16) 73(12) 89(13) 23(10) 3(8) 0.229
Depression, n (%) 389(21) 59(19) 113(17) 153(23) 65(29) 11(30) 0.001
Sedative treatment, n (%) 442(24) 53(17) 114(18) 175(27) 86(38) 14(38) <0.001
Uric acid agents, n (%) 168(9) 27(9) 62(10) 66(10) 10(4) 3(8) 0.117
Smoking, n (%)
Never 795(43) 91(29) 254(41) 314(48) 114(51) 22(61) <0.001
Former 828(45) 168(55) 289(47) 280(43) 82(36) 9(25)
Current 212(11) 48(15) 73(12) 58(9) 28(12) 5(14)
Adherence to energy-restricted MedDiet
(score from 0 to 17 items), mean± SD 8.6 ± 2.7 8.2 ± 2.7 8.7 ± 2.7 8.5 ± 2.7 8.7 ± 2.7 9.6 ± 2.9 0.017
Compliance of MVPA recommendations a, n (%) 352(19) 51(16) 133(21) 134(20) 33(13) 4(11) 0.027
Education status, n (%)
Primary education 909(49) 136(44) 278(45) 338(52) 132(59) 25(67) <0.001
Secondary education 494(27) 76(25) 175(28) 185(28) 52(23) 6(16)
Academic/graduate 413(22) 92(30) 157(25) 124(18) 35(15) 5(13)
Employment status, n (%)
Working 376(20) 92(30) 148(24) 110(17) 25(11) 1(2) <0.001
Non-working 441(25) 62(18) 147(23) 182(26) 71(29) 10(26)
Retired 1017(55) 160(53) 331(54) 363(55) 136(60) 27(73)
Marital status, n (%)
Single/divorced 267(14) 49(16) 95(15) 93(14) 22(10) 8(21) 0.029
Married 1369(75) 227(74) 471(77) 477(73) 170(76) 24(65)
Widower 196(11) 31(10) 46(7) 82(12) 32(14) 5(13)
Data is presented as mean ± SD unless otherwise indicated. Abbreviations: BMI, body mass index; MedDiet, Mediterranean Diet; MVPA, moderate to vigorous physical activity.
a Recommendations for MVPA set at ≥150 min/week for elderly persons, based on accelerometry-derived 10-min bout MVPA.The p-value for differences between categories of nocturnal
sleep duration was calculated by chi-squared or one-way analysis of variance test using the Bonferroni rule to correct for type I error in the post-hoc multiple comparisons for categorical
and continuous variables, respectively.
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Table 2. Sleep and biochemical parameters of the study population from Prevención con Dieta Mediterránea-Plus trial across categories of nocturnal sleep duration.
Categories of Nocturnal Sleep Duration (h)
Total
n = 1842
<6 h
n = 308
6–<7 h
n = 618
7–<8 h
n = 654
8–<9 h
n = 225
≥9 h
n = 37 p-Value
Sleep parameters
Sleep duration, mean± SD, h 6.9 ± 1.1 5.3 ± 0.7 6.5 ± 0.3 7.4 ± 0.3 8.4 ± 0.2 9.3 ± 0.3 <0.001
Sleep variability, median
interquartile range, h 0.8 0.6; 1.1 0.90.6; 1.2 0.8 0.6; 1.0 0.8 0.6; 1.1 0.7 0.6; 1.0 0.8 0.6; 0.9 <0.001
Napping duration, median
interquartile range, min 76.749.7; 109.8 64.842.3; 91.1 67.742.9; 97.1 78.8 53.5; 108.6 113.4 79.9; 145.2 163.9 109.8; 203.5 <0.001
Biochemical parameters
Serum uric acid, mean ± SD, mg/dL 6.0 ± 1.4 6.3 ± 1.5 6.1 ± 1.5 5.9 ± 1.4 5.7 ± 1.4 5.4 ± 1.5 <0.001
Creatinine, mean ± SD, mg/dL 0.83 ± 0.2 0.85 ± 0.2 0.82 ± 0.2 0.83 ± 0.2 0.83 ± 0.2 0.80 ± 0.2 0.165
Serum uric acid to creatinine ratio 7.4 ± 1.9 7.6 ± 1.9 7.7 ± 1.9 7.4 ± 1.8 7.1 ± 1.8 6.9 ± 2.2 <0.001
Leukocytes, mean ± SD, counts 6.7 ± 1.7 6.9 ± 1.8 6.7 ± 1.7 6.5 ± 1.6 6.8 ± 1.8 6.7 ± 1.4 0.090
Data is presented as mean ± SD or median interquartile range. The p-value for differences between categories of nocturnal sleep duration was calculated by chi-squared or one-way
analysis of variance test using the Bonferroni rule to correct for type I error in the post-hoc multiple comparisons for categorical and continuous variables, respectively. In case of
non-normally distributed variables we performed Kruskal–Wallis test with Mann–Whitney tests in the post-hoc multiple comparisons.
Table 3. β-coefficients (95% Confidence Interval (CI)) for association between serum uric acid, serum uric acid to creatinine ratio, and sleep measures (sleep duration,
sleep variability (log-transformed)).
Model 1 p-Value Model 2 p-Value Model 3 p-Value
SUA
Sleep duration (h) −0.08 (−0.14, −0.02) 0.008 −0.07 (−0.13, −0.01) 0.047 −0.06 (−0.13, 0.01) 0.050
Sleep variability (h) −0.29 (−0.60, 0.01) 0.056 −0.26 (−0.56, 0.05) 0.100 −0.25 (−0.56, 0.05) 0.101
SUA/Cr
Sleep duration (h) −0.20 (−0.29, −0.12) <0.001 −0.15 (−0.24, −0.06) 0.001 −0.15 (−0.24, −0.06) 0.001
Sleep variability (h) −0.30 (−0.72, 0.12) 0.163 −0.23 (−0.66, 0.19) 0.279 −0.24 (−0.67, 0.19) 0.272
Abbreviations: SUA, serum uric acid; Cr, creatinine. Model 1 adjusted for sex, age (years). Model 2 adjusted for Model 1 plus body mass index (kg/m2), marital status (single/divorced,
married, widower), employment (working, nonworking, retired), education (primary education, secondary education, academic/graduate), smoking habit (current smoker, past
smoker, never smoked), sedative treatment (yes/no), sleep apnea (yes/no), type 2 diabetes (yes/no), uric acid agents (yes/no), hypertension (yes/no), depression (yes/no), 17-item
energy-restricted Mediterranean diet, compliance to MVPA recommendations set at ≥150 min/week (yes/no), time spent in sustained inactivity bouts (“daytime napping”, min/day) and
intervention center. Model 3 adjusted for Model 2 plus leukocytes.
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4. Discussion
In the present cross-sectional study of 1842 elderly participants from the PREDIMED-Plus trial,
we observed inverse associations of sleep duration with SUA concentrations and the ratio of SUA
to creatinine.
Elevations in catecholamine levels have been reported in participants with sleep loss [7], which
may increase nucleotide turnover, thus enhancing endogenous uric acid production [21]. Furthermore,
sleep deprivation may activate proteolytic pathways [8,9], leading to the production of purines and
uric acid. Our results also suggest that the association between sleep duration and uric acid may
be mediated by inflammation. Sleep deprivation may worsen systemic inflammation, as shown in
two experimental studies in which the white blood cell and neutrophil counts were significantly
higher after sleep restriction [18,19], leading to an increase in serum uric acid concentrations. Given
the cross-sectional nature of this study, we cannot exclude the possibility that raised uric acid
concentrations may cause inflammation by increasing leukocytes [20]. A previous study has observed
that when levels of cytokines were compared between insomniacs and normal sleepers, there was a
significant increase of cytokines in those with low sleep quality [22]. Another study found that chronic
inflammation from any cause can lead to insomnia [23]. Whether both SUA and sleep loss can increase
inflammatory markers requires further investigation. The increase in SUA to creatinine ratio in short
sleepers may reflect the uric acid loading and/or a reduction in creatinine levels in circulation due to
increased diuresis [24].
The current findings should be interpreted on the basis of the study’s limitations. First, the cross-
sectional design does not allow any causal inference of the observed associations to be made. Second,
the participants were elderly Mediterranean individuals with metabolic syndrome, thus, results cannot
be extrapolated to other populations. Third, even though we adjusted for several potential confounders,
residual confounding may remain. Fourth, we cannot exclude accuracy issues related to the derived
sleep data. Using actigraphy in concert with complementary subjective methods such as sleep diaries
may reduce these uncertainties.
In conclusion, “cross-sectional” evidence is useful to support the hypothesis that longer sleep
duration is associated with lower SUA concentrations and lower SUA to creatinine ratio in elderly
participants at high cardiovascular risk. Further longitudinal studies are required to clarify the
temporal nature of this relationship and elucidate possible mechanisms underlying these observations.
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